Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
New portrait of the oldest-known supernova | Space photo of the day for March 27, 2026 - 2Winona Ryder didn't take the 'Stranger Things' plot lightly. How 'otherworldly' grief and a kidnapping in her hometown informed her character.
- 32024 Moving Styles for Kitchen Redesigns
- 4Vote in favor of your #1 Kind of Cap
- 5The teen queen bee of 'Laguna Beach' is now a 'cringey' mom
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- This Week In Space podcast: Episode 203 — China Rising
- The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- In these U.S. groups, deaths now exceed births. What’s happening?
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- Countdown begins for long-awaited Artemis II moon mission
- France's Senate backs ban on social media platforms for under-15s
- An 'explosion' of solo-agers are struggling with rising costs and little support: 'I'm flying without a net'
